Anondita Medicare FY26: High Growth, Higher Ambition, and a Big Export Pivot

/n/n# Anondita Medicare FY26: High Growth, Higher Ambition, and a Big Export Pivot/n/nAnondita Medicare Limited, formerly known as Anondita Healthcare, closed FY26 with a sharp step-up in scale. In the company’s investor presentation for the year ended March 31, 2026, consolidated revenue from operations is reported at INR 137.42 crore, up from INR 76.99 crore in FY25. Profitability also improved. Consolidated EBITDA rose to INR 51.51 crore with an EBITDA margin of 37.48%, while consolidated net profit increased to INR 34.30 crore with a net profit margin of 24.96%./n/nH2 FY26 was the clear driver. The presentation reports H2 FY26 revenue from operations of INR 83.32 crore versus INR 45.59 crore in H2 FY25, along with H2 FY26 net profit of INR 21.28 crore versus INR 10.47 crore in H2 FY25. On the earnings call, management attributed the H2 skew partly to the government ordering pattern, where procurement and deliveries tend to peak in the last quarter as annual budgets get utilised./n/n/n| Metric (Consolidated) | FY26 | FY25 |/n|---|---:|---:|/n| Revenue from operations (INR crore) | 137.42 | 76.99 |/n| EBITDA (INR crore) | 51.51 | 25.79 |/n| EBITDA margin | 37.48% | 33.50% |/n| Net profit (INR crore) | 34.30 | 16.50 |/n| Net profit margin | 24.96% | 21.44% |/n| Operating cash flow (INR crore) | 10.64 | -7.40 |/n/n/n## Manufacturing scale and capacity: the FY26 execution backbone/n/nThe presentation positions capacity expansion as the core operating lever. The company’s Noida facility is described as having 15 operational manufacturing lines, with additional lines under work in progress. A capacity table in the presentation shows installed capacity for condoms at 5,620 million pieces in FY24 and FY25, increasing to 8,690 million pieces in FY26. Utilisation is reported to have risen to 80.67% in FY26, up from 46.05% in FY25./n/nOn the call, the managing director also claimed that the company fabricates manufacturing machines in-house and holds patents related to these machines, which in his view reduces installation time and capital intensity compared to peers. While the transcript does not provide patent numbers or audited cost comparisons, the operational narrative consistently ties expansion speed to this in-house capability./n/nThe funding and investment plan is also explicitly discussed. The presentation indicates an estimated project cost of around INR 75 crore plus taxes for ongoing expansion, to be funded through internal accruals, debt, and potentially a preferential issue. It also discloses an R and D allocation of INR 2.85 crore, focused on premium condom variants, non-latex options, female condom development, and diagnostics innovation./n/n/n## Exports and certifications: building the compliance bridge/n/nA major theme across the presentation and the call is export access through certifications. The company highlights receipt of MDSAP certification under ISO 13485:2016, with stated scope covering manufacturing, marketing, and distribution of male and female condoms. The presentation states that MDSAP enables marketing across five regulated jurisdictions: Australia, Brazil, Canada, Japan, and the United States. It also shows an SABS certification for natural rubber latex male condoms under SANS 4074:2017, which the company links to South Africa and Africa-focused tenders./n/nIn the call, management described South Africa as a near-term opportunity. The managing director said the company had been approved for supply for the next five years and that only the purchase order was pending. He also discussed ambitions to execute a meaningful share of South Africa’s annual requirement. These statements are directional and not supported by a quantified order book disclosure in the transcript, but they indicate where management expects incremental volumes to come from./n/nIn addition, the company’s presentation and call repeatedly reference UNFPA or UN qualification. The presentation notes that UN qualification is in advanced stages and suggests exports could begin by end-FY26 or early next year. On the call, management stated that the UN process was in the pipeline and mentioned an early hearing in Geneva on June 16. The documents do not provide a definitive approval timeline, but the repeated emphasis indicates that institutional procurement channels are part of the strategy./n/n/n## Revenue mix and the working capital reality/n/nA rare, explicit product-level mix disclosure appears in the Q and A section of the call. The CFO stated that FY26 revenue included approximately INR 118 crore from condoms and about INR 19 crore from gloves, with the remainder coming from other products such as pregnancy kits, medicines, and other glove categories. The investor presentation does not provide an audited segment note with these categories, but the call provides this high-level split./n/nWorking capital is a meaningful operational factor in FY26. Consolidated cash flow from operations in the presentation is INR 10.64 crore, while consolidated net profit is INR 34.30 crore. During the call, the CFO explained that a significant portion of annual revenue was booked in the fourth quarter and that government receivables typically have a minimum 120-day realisation cycle, delaying cash conversion. Management added that export customers typically pay advances or use letters of credit, which could improve cash flow consistency./n/nThis is one of the more grounded parts of the transcript. It acknowledges a structural cash conversion issue tied to the government business cycle and offers a plausible mitigation path via exports. It does not quantify the expected improvement, but it frames cash conversion as a monitoring point rather than a hidden risk./n/n/n## Female condoms: a high-margin narrative, but still early-stage/n/nThe most ambitious part of the earnings call centers on female condoms. The investor presentation positions female condoms as a premium category with materially higher margin potential, citing a 30 to 40% higher margin potential compared to traditional male condoms. It also notes that global supply is limited and demand is supported by government and donor programs./n/nOn the call, management stated that female condom trial production has been completed using the company’s in-house fabricated patented machine and that the product is registered with the Government of India. The managing director also claimed that the company is registered in Brazil for supply of female latex and non-latex condoms. These are important statements because they imply early regulatory and product-readiness steps./n/nHowever, the financial projections shared verbally were extremely aggressive. Management described current female condom capacity as 5 million pieces and discussed plans to scale capacity to 120 million pieces each for female latex and female non-latex. He also claimed that 25% utilisation could translate into about INR 330 crore revenue and about INR 150 crore profit from female condoms in FY27. The transcript does not provide contracts, tender documents, or binding order details to support these figures. As a result, investors should treat them as aspirational scenario commentary rather than verified guidance./n/n/n## What to watch next/n/nThe company’s own target slide in the presentation calls for 60 to 70% revenue growth by FY27 with EBITDA margins around 30%, alongside a stated aim of 25% export contribution by FY27. Certifications like MDSAP and SABS strengthen the export narrative, and capacity expansion has already translated into a stronger FY26 base./n/nThe more difficult part will be execution quality in three areas: converting certifications into repeat export orders, improving cash conversion as the mix evolves, and validating the female condom thesis through real tenders and shipments rather than projections./n/nAnondita Medicare enters FY27 with a credible FY26 growth print and a clear strategic pivot. The next year will decide whether the export and female condom story becomes a revenue stream or remains a promise./n